Dr. Lal PathLabs Ltd reported a strong financial performance for the fourth quarter ended March 31, 2025, with consolidated net profit rising 81% year-on-year to ₹155.5 crore, up from ₹85.8 crore in Q4 FY24. The sharp increase was driven by higher diagnostic volumes and efficient cost management.
The company’s total income stood at ₹628.4 crore for Q4 FY25, compared to ₹563.8 crore in the same quarter last year, marking an 11.4% YoY growth. Revenue from operations rose to ₹602.6 crore, compared to ₹545.4 crore in Q4 FY24.
On the expense front, total costs for the quarter came in at ₹475 crore, slightly up from ₹443.9 crore in Q4 FY24. Key contributors included employee benefits (₹115.4 crore), cost of materials (₹117.8 crore), and fees to collection partners (₹77.6 crore).
Profit before tax grew significantly to ₹153.4 crore in Q4 FY25, compared to ₹119.9 crore in the same quarter last year. Tax expenses stood at a net credit of ₹2.1 crore, aided by deferred tax adjustments.
For the full year FY25, Dr. Lal PathLabs reported:
-
Total income: ₹2,554.8 crore (up from ₹2,295.8 crore in FY24)
-
Net profit: ₹492.2 crore (up from ₹362.3 crore in FY24)
-
Total expenses: ₹1,930.1 crore
-
EBITDA margin: Improved on yearly basis (figures inferred from performance)
The results underscore the company’s continued growth in the diagnostics space, driven by rising test volumes and expanding presence in key regions.
